Last week, Astrazeneca plc tapped Mirati Therapeutics Inc. for a partnership that will explore a pairing of the spectrum-selective histone deacetylase, or HDAC, blocker mocetinostat with the anti-programmed death-ligand 1 (PD-L1) candidate durvalumab (MEDI4736).